We monitored tumour formation by in vivo imaging and found that the luciferase activities of the tumours derived from CD24−/low/CD44+ cell populations treated with DHMEQ were significantly decreased compared with that of untreated cell-derived tumours (Figure 5). The gene discussed is CD44; the disease is neoplasm.